Equities Analysts Issue Forecasts for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for Zevra Therapeutics in a report released on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($1.93) per share for the year, up from their previous forecast of ($1.97). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.96) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period in the prior year, the company posted ($0.40) earnings per share.

A number of other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Guggenheim started coverage on Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 target price for the company. JMP Securities assumed coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Maxim Group raised their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.57.

Zevra Therapeutics Stock Down 4.9 %

Shares of NASDAQ:ZVRA opened at $8.11 on Friday. The company’s fifty day moving average is $8.79 and its two-hundred day moving average is $7.59. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The stock has a market capitalization of $432.88 million, a price-to-earnings ratio of -4.12 and a beta of 2.01.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC increased its stake in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after buying an additional 5,940 shares during the period. Hunter Associates Investment Management LLC bought a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $92,000. XTX Topco Ltd acquired a new position in shares of Zevra Therapeutics during the third quarter valued at approximately $94,000. Intech Investment Management LLC bought a new stake in Zevra Therapeutics during the third quarter worth approximately $95,000. Finally, SG Americas Securities LLC acquired a new stake in Zevra Therapeutics in the third quarter worth approximately $105,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.